

Express Mail Label No.: E7 24715033 US
Date of Deposit: February 3, 2003

PATENT APPLICATION
Attorney Docket No. 00689-511 CIP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Robert S. Landsman, Ph.D.
Art Unit : 1647
Applicants : Johansen and Sah
Serial No. : 09/804,615 (Confirmation No.: 3157)
Filed : March 12, 2001
For : NOVEL NEUROTROPHIC FACTORS

February 3, 2003
New York, New York

Hon. Commissioner of Patents
Washington, D.C. 20231

12/8
09/3
2/12/03
RECEIVED
FEB 06 2003
TECH CENTER 1600/2900

AMENDMENT AND REPLY TO RESTRICTION REQUIREMENT

This is in response to the September 3, 2003 Restriction Requirement in the above-identified application. Applicants have petitioned herewith to extend the time for response to that action by four months, up to and including February 3, 2003. No other fee is believed due in connection with this response. However, the Director is hereby authorized to charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 00689-511 CIP.

THE RESTRICTION REQUIREMENT

The Examiner has identified six groups from which applicants must elect:

- I. Claims 1-20, 35 and 36 drawn to truncated neuroblastin polypeptide, including that of SEQ ID NO:2, and a pharmaceutical composition, classified in class 530, subclass 350.
- II. Claims 21-23 in part, 25-34, and 37 drawn to a nucleic acid molecule encoding a neuroblastin polypeptide, as well as vectors, host cells, and a process for producing a polypeptide, and a pharmaceutical composition, classified in class 435, subclass 69.1.